Search Results
Sep 08, 2026, 09:09 ET Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite
More news about: Berger Montague
Aug 31, 2026, 14:35 ET Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite
More news about: Berger Montague
Aug 21, 2026, 04:38 ET ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA
action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of
More news about: DJS Law Group LLP
Aug 21, 2026, 04:38 ET ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of
More news about: Schall, Brown & Schwartz LLP
Aug 17, 2026, 12:10 ET Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite
More news about: Berger Montague
Aug 10, 2026, 15:24 ET ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
failed to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; and (4) as a result, defendants' statements about ADMA Biologics' business, operations,
More news about: THE ROSEN LAW FIRM, P. A.
Aug 10, 2026, 08:30 ET ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline
that:ADMA Biologics engaged in an undisclosed related party transaction;ADMA Biologics used channel stuffing to create an appearance of revenue;ADMA Biologics lacked adequate internal controls; andAs a result, Defendants' statements about ADMA Biologics' business,
More news about: Hagens Berman Sobol Shapiro LLP
Aug 10, 2026, 03:40 ET ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA
action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of
More news about: DJS Law Group LLP
Aug 10, 2026, 03:38 ET ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of
More news about: Schall, Brown & Schwartz LLP
Aug 09, 2026, 14:59 ET DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026
that:ADMA Biologics engaged in an undisclosed related party transaction;ADMA Biologics used channel stuffing to create an appearance of revenue;ADMA Biologics lacked adequate internal controls; andAs a result, Defendants' statements about ADMA Biologics' business,
More news about: Hagens Berman Sobol Shapiro LLP
Aug 07, 2026, 10:38 ET MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
lawsuit. Captioned Mazzarino v. ADMA Biologics, Inc., No. 26-cv-06918 (D.N.J.), the ADMA Biologics class action lawsuit charges ADMA Biologics as well as certain of ADMA Biologics' executive officers with violations of the Securities Exchange Act of 1934.
More news about: Robbins Geller Rudman & Dowd LLP
Aug 06, 2026, 19:59 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA
Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected]
More news about: Pomerantz LLP
Aug 06, 2026, 17:42 ET ADMA Biologics, Inc. Deadline: ADMA Investors with Losses in Excess of $100K Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
failed to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; and (4) as a result, defendants' statements about ADMA Biologics' business, operations,
More news about: THE ROSEN LAW FIRM, P. A.
Aug 06, 2026, 13:32 ET ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
that:ADMA Biologics engaged in an undisclosed related party transaction;ADMA Biologics used channel stuffing to create an appearance of revenue;ADMA Biologics lacked adequate internal controls; andAs a result, Defendants' statements about ADMA Biologics' business,
More news about: Hagens Berman Sobol Shapiro LLP
Aug 06, 2026, 04:12 ET ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of
More news about: Schall, Brown & Schwartz LLP
Aug 06, 2026, 04:10 ET ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA
action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of
More news about: DJS Law Group LLP
Aug 05, 2026, 07:20 ET Robbins LLP Reminds ADMA Investors of the August 10, 2026 Lead Plaintiff Deadline; Contact the Firm for Information About Recovering Your Losses
that:ADMA Biologics engaged in an undisclosed related party transaction;ADMA Biologics used channel stuffing to create an appearance of revenue;ADMA Biologics lacked adequate internal controls; andas a result, defendants' statements about ADMA Biologics' business,
More news about: Robbins LLP
Aug 04, 2026, 12:53 ET ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
844-916-0895Alleged Wrongdoing in ADMA Biologics Lawsuit: The lawsuit alleges that Defendants artificially inflated stock value by misrepresenting and failing to disclose that:ADMA Biologics engaged in an undisclosed related party transaction;ADMA Biologics used
More news about: Hagens Berman Sobol Shapiro LLP
Aug 04, 2026, 10:09 ET ADMA DEADLINE: The Gross Law Firm Reminds ADMA Biologics, Inc. Investors of Upcoming Securities Class Action Deadline
failed to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; (4) as a result, defendants' statements about ADMA Biologics' business, operations,
More news about: The Gross Law Firm
Aug 04, 2026, 06:36 ET ADMA Stock Drop: ADMA Biologics Channel Stuffing Allegations Lead to 29% Stock Drop and Securities Fraud Class Action for Investors
investors in ADMA securities. The class action is pending in the U.S. District Court for the District of New Jersey. It is captioned Mazzarino v. ADMA Biologics, Inc., et al., No. 26-cv-6918.Why is ADMA Biologics Being Sued for Securities Fraud? ADMA has been sued
More news about: Bleichmar Fonti & Auld LLP
Aug 03, 2026, 20:50 ET ONE WEEK INVESTOR DEADLINE ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead ADMA Investor Class Action Lawsuit before August 10, 2026 Deadline
acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the "Class Period"), have until Monday, August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captioned Mazzarino v. ADMA Biologics,
More news about: Robbins Geller Rudman & Dowd LLP
Aug 03, 2026, 09:54 ET DEADLINE APPROACHING: Berger Montague Advises ADMA Biologics, Inc. (NASDAQ: ADMA) Investors to Inquire About a Securities Fraud Class Action by August 10, 2026
Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company") on behalf of investors who purchased or acquired ADMA common stock during the period from August 9, 2024 through March 25, 2026 (the "Class
More news about: Berger Montague
Aug 03, 2026, 03:02 ET ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of
More news about: Schall, Brown & Schwartz LLP
Aug 03, 2026, 03:01 ET ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA
action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of
More news about: DJS Law Group LLP
Aug 01, 2026, 19:02 ET ADMA Deadline: ADMA Investors with Losses in Excess of $100K Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
failed to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; and (4) as a result, defendants' statements about ADMA Biologics' business, operations,
More news about: THE ROSEN LAW FIRM, P. A.